Research map: De-escalation of antiplatelet therapy to evaluate platelet reactivity and clinical outcomes after coronary stenting in patients at high bleeding risk and recent acute coronary syndrome: Rationale and design of the DESC-HBR trial

Back to the article

Papers in this map

  1. Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes · Lars C. Wallentin · 2009 · 7157 citations · Cited by this paper
  2. Age modifies the prognostic value of post-procedural high-sensitivity troponin T for mortality in patients with acute coronary syndrome: A registry study of 14,210 patients · 2026 · Related
  3. Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes · Stephen D. Wiviott · 2007 · 6826 citations · Cited by this paper
  4. Long-term clinical prognostic utility of the SYNTAX score in all-comer patients with coronary artery disease who underwent percutaneous coronary intervention · 2026 · Related
  5. Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment Elevation · The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators · 2001 · 6517 citations · Cited by this paper
  6. Expert perspectives on de-escalation of antiplatelet therapy – Beyond the guidelines: Insights from the cardiovascular research technologies 2026 meeting · 2026 · Related
  7. 2023 ESC Guidelines for the management of acute coronary syndromes · Robert A. Byrne · 2023 · 5145 citations · Cited by this paper
  8. Routine echocardiography after left atrial appendage closure: The impact of patient selection and clinical triage on outcomes · 2026 · Related
  9. Standardized Bleeding Definitions for Cardiovascular Clinical Trials · Roxana Mehran · 2011 · 4533 citations · Cited by this paper
  10. Angiography-derived physiology and biomechanics: The path toward a comprehensive plaque characterization reply · 2026 · Related
  11. Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction · Marc P. Bonaca · 2015 · 2003 citations · Cited by this paper
  12. An assessment of the accuracy of a novel peripheral artery disease scoring system to identify obstructive coronary artery disease in patients with severe aortic stenosis · 2026 · Related
  13. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials · Francesco Costa · 2017 · 1190 citations · Cited by this paper
  14. Incidence and prognostic value of electrocardiographic changes in patients with myocardial injury after elective PCI · 2026 · Related
  15. Standardized End Point Definitions for Coronary Intervention Trials: The Academic Research Consortium-2 Consensus Document · Héctor M. García‐García · 2018 · 985 citations · Cited by this paper
  16. Residual leaks after left atrial appendage occlusion · 2026 · Related
  17. Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention · Philip M. Urban · 2019 · 828 citations · Cited by this paper
  18. Diagnostic and clinical management of non-obstructive myocardial ischemia in patients with long Covid-19 syndrome and new-onset chest pain: Design and rationale of the long Covid-19 INOCA trial · 2026 · Related
  19. A Genotype-Guided Strategy for Oral P2Y 12 Inhibitors in Primary PCI · Daniel M.F. Claassens · 2019 · 654 citations · Cited by this paper
  20. Device-specific failure patterns of guide catheter extensions in percutaneous coronary intervention: A contemporary MAUDE database analysis (2022–2025) · 2026 · Related
  21. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial · Dirk Sibbing · 2017 · 612 citations · Cited by this paper
  22. Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome · Byeong‐Keuk Kim · 2020 · 584 citations · Cited by this paper
  23. Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study · Thomas Cuisset · 2017 · 417 citations · Cited by this paper
  24. International Expert Consensus on Switching Platelet P2Y 12 Receptor–Inhibiting Therapies · Dominick Joseph Angiolillo · 2017 · 396 citations · Cited by this paper
  25. 6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial · Joo‐Yong Hahn · 2018 · 374 citations · Cited by this paper
  26. Bleeding and stent thrombosis on P2Y 12 -inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention · Dániel Aradi · 2015 · 368 citations · Cited by this paper
  27. 2024 AHA/ACC/ACS/ASNC/HRS/SCA/SCCT/SCMR/SVM Guideline for Perioperative Cardiovascular Management for Noncardiac Surgery: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines · Annemarie Thompson · 2024 · 349 citations · Cited by this paper
  28. Comparison of Clopidogrel Monotherapy After 1 to 2 Months of Dual Antiplatelet Therapy With 12 Months of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome · Hirotoshi Watanabe · 2022 · 324 citations · Cited by this paper
  29. Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis · Mattía Galli · 2021 · 243 citations · Cited by this paper
  30. Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial · Hyo‐Soo Kim · 2020 · 211 citations · Cited by this paper
  31. Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised trial · Chan Joon Kim · 2021 · 211 citations · Cited by this paper
  32. Impaired Responsiveness to the Platelet P2Y12 Receptor Antagonist Clopidogrel in Patients With Type 2 Diabetes and Coronary Artery Disease · Dominick Joseph Angiolillo · 2014 · 185 citations · Cited by this paper
  33. Defining Strategies of Modulation of Antiplatelet Therapy in Patients With Coronary Artery Disease: A Consensus Document from the Academic Research Consortium · Davide Capodanno · 2023 · 179 citations · Cited by this paper
  34. Stopping Aspirin Within 1 Month After Stenting for Ticagrelor Monotherapy in Acute Coronary Syndrome: The T-PASS Randomized Noninferiority Trial · Sung‐Jin Hong · 2023 · 165 citations · Cited by this paper
  35. Bleeding avoidance strategies in percutaneous coronary intervention · Davide Capodanno · 2021 · 164 citations · Cited by this paper
  36. Dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk: a meta-analysis of randomized trials · Francesco Costa · 2022 · 138 citations · Cited by this paper
  37. International Consensus Statement on Platelet Function and Genetic Testing in Percutaneous Coronary Intervention · Dominick Joseph Angiolillo · 2024 · 118 citations · Cited by this paper
  38. Short Duration of DAPT Versus De-Escalation After Percutaneous Coronary Intervention for Acute Coronary Syndromes · Claudio Laudani · 2022 · 114 citations · Cited by this paper
  39. De-escalation or abbreviation of dual antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention: a Consensus Statement from an international expert panel on coronary thrombosis · Diana Adrienne Gorog · 2023 · 98 citations · Cited by this paper

Source: OpenAlex (CC0)